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Abstract
Not only is Asia the most populous region in the world, but inappropriate therapy, including self-medication with over-the-counter
antimicrobial agents, is a common response to infectious diseases. The high antibiotic selective pressure among the overcrowded
inhabitants creates an environment that is suitable for the rapid development and efﬁcient spread of numerous multidrug-resistant
pathogens. Indeed, Asia is among the regions with the highest prevalence rates of healthcare-associated methicillin-resistant Staphylococcus
aureus (HA-MRSA) and community-associated methicillin-resistant S. aureus (CA-MRSA) in the world. Most hospitals in Asia are endemic
for multidrug-resistant methicillin-resistant S. aureus (MRSA), with an estimated proportion from 28% (in Hong Kong and Indonesia) to
>70% (in Korea) among all clinical S. aureus isolates in the early 2010s. Isolates with reduced susceptibility or a high level of resistance to
glycopeptides have also been increasingly identiﬁed in the past few years. In contrast, the proportion of MRSA among community-associated
S. aureus infections in Asian countries varies markedly, from <5% to >35%. Two pandemic HA-MRSA clones, namely multilocus sequence
type (ST) 239 and ST5, are disseminated internationally in Asia, whereas the molecular epidemiology of CA-MRSA in Asia is characterized
by clonal heterogeneity, similar to that in Europe. In this review, the epidemiology of S. aureus in both healthcare facilities and communities
in Asia is addressed, with an emphasis on the prevalence, clonal structure and antibiotic resistant proﬁles of the MRSA strains. The novel
MRSA strains from livestock animals have been considered to constitute a public health threat in western countries. The emerging
livestock-associated MRSA strains in Asia are also included in this review.
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Introduction
Staphylococcus aureus is a major cause of numerous infections
in both communities and healthcare facilities, and is increas-
ingly showing resistance to multiple antimicrobial agents [1,2].
The development of resistance to multiple drugs, including
glycopeptides, has caused substantial difﬁculty in the manage-
ment of staphylococcal infections, and has been long been a
healthcare concern worldwide [3,4]. Asia is among the regions
with the highest incidence of methicillin-resistant S. aureus
(MRSA) in the world [5–7]. Vancomycin-intermediate S. aureus
(VISA) strains and vancomycin-resistant S. aureus (VRSA)
strains are also being increasingly identiﬁed in certain countries
in this region [8–11]. Furthermore, similar to the reports in
Europe, a novel MRSA strain that had spread in livestock
animals was recently identiﬁed as a potential human pathogen
in Asia [12]. Given the changing epidemiology, timely updated
information on epidemic S. aureus strains in local and neigh-
bouring countries is essential for the prevention and control of
this pathogen. This information is also important for clinicians
dealing with staphylococcal diseases. In this article, we
comprehensively review the currently available data from
Asian countries, and present the epidemiology, including the
prevalence, molecular features, and antimicrobial resistance
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proﬁles, of healthcare-associated MRSA (HA-MRSA), commu-
nity-associated MRSA (CA-MRSA) and livestock-associated
MRSA (LA-MRSA) in Asian countries.
HA-MRSA in Asia
MRSA is prevalent in nearly all healthcare facilities, and
constitutes a huge infectious disease burden in Asia. The
incidence varies signiﬁcantly between different countries, and
has changed over time [13–17]. Molecular epidemiology
studies have demonstrated that the majority of HA-MRSA
strains from different countries are of the same genotype,
suggesting international dissemination of a few health-
care-associated clones in this region. However, most reports
have been from certain relatively high-income countries,
including Taiwan, Japan, Korea, Hong-Kong SAR, and Singa-
pore. The information is either fragmentary or completely
unavailable for the majority of the resource-limited countries
in Southeast Asia and South Asia, and this has substantially
limited our understanding of the epidemiology of staphylo-
coccal diseases in this region [18]. In this section, we highlight
the incidence, antibiotic resistance proﬁles and molecular
features of HA-MRSA in Asian countries. Selected reports
regarding the incidence of HA-MRSA in Asian countries are
shown in Table 1.
East Asia
Taiwan, Korea, and Japan. Although increasing numbers of
MRSA outbreaks were reported in Europe and the USA in the
1960s after the emergence of the ﬁrst MRSA strain in the UK,
MRSA was rarely documented before 1980 in East Asia. Japan
was an exception; S. aureus with low-level resistance to
methicillin was ﬁrst identiﬁed in the early 1960s, but with a
very low incidence (<3%) [19,20]. In Taiwan and Korea, MRSA
had never been reported until 1981 and 1986, respectively
[21,22]. S. aureus isolates collected during 1976–1978 in a
university-afﬁliated teaching hospital in northern Taiwan
showed 100% susceptibility to oxacillin [23]. The occurrence
of nosocomial MRSA diseases remained at a low rate, and 0.2–
0.9 episodes were identiﬁed per 1000 discharges in a hospital
in the early 1980s [24].
The rate of MRSA increased remarkably in the next
20 years, from 1980 to 2000, in East Asia. In Taiwan, the
proportion of MRSA among all nosocomial S. aureus isolates
increased from 20.2% in 1981–1986 to 64.8% in 1993–1998,
and further increased to 69.3% in 1999 [15,25]. Two
subsequent multicentre studies consistently showed average
MRSA rates of c. 60% for all S. aureus isolates and 50% for
blood isolates in this island in 1998–2000 [7,26]. In Japan, a
nationwide study including 43 hospitals showed that 58.6% of
clinical S. aureus isolates were MRSA in 1990 [27]. The rate
appeared to be continuously increasing, as shown by the
SENTRY study, in which the rate of MRSA, obtained from
three major hospitals in Japan, was 67–71.6% in 1998–2001
[7,28,29]. Nationwide surveillance in Korea also showed a
mean MRSA rate of 72% for all clinical S. aureus isolates from
25 hospitals in 1998 [30]. The MRSA rate in East Asian
countries appeared to reach its highest level at the end of the
last millennium.
After the year 2000, the rate of HA-MRSA had still not
signiﬁcantly changed, and was still extremely high in Korea.
The ANSORP study, including seven hospitals in Korea,
showed an average MRSA rate of 77.6% for nosocomial
S. aureus isolates during 2004–2006. The most recent report
of the Regional Resistance Surveillance (RRS) programme
showed that 73% of the clinical S. aureus isolates from two
hospitals in Korea were MRSA in 2011 [31]. Korea has the
highest MRSA rate among the 12 surveillance countries in the
RSS programme. The epidemiology of HA-MRSA changed after
2000 in Taiwan and in Japan, where a declining trend of MRSA
incidence was observed [31,32]. From 2000 to 2010, the
proportion of MRSA among all S. aureus isolates obtained from
patients with nosocomial bloodstream infections (BSIs)
decreased from 68.8% in 2000 to 55.9% in 2010 in Taiwan
(p 0.01) [33]. The incidence also signiﬁcantly decreased, from
27.9 to 12.3 per 100 000 patient-days, with an annual decline
of 8.5% over the 10-year study period in a hospital in Taiwan
(p <0.001) [33]. The RRS programme reported an MRSA rate
of 41% in Japan in 2011, which was signiﬁcantly lower than the
values reported in SENTRY studies during 1998–2001
[7,28,29]. A reduction in the number of HA-MRSA infections
was also seen in western countries during the same period
[34–36]. Hand hygiene, antibiotic stewardship and surveillance
programmes were considered to be possible explanations for
the decline in HA-MRSA infections [37–40]. The change in
MRSA strains, owing to the entry of CA-MRSA strains into
hospitals, has also been proposed as a possible explanation
[34].
Hong Kong and China. Epidemiological information on MRSA
was largely lacking in China before 1998. The incidence
remained at a relatively low level in the early 2000s, as shown
by the SENTRY studies, in which MRSA accounted for 13–
27.8% of clinical S. aureus isolates from three hospitals in
1998–2001 [7,29]. The rates increased dramatically to 50–62%
in 2004–2005 in two multicentre studies [41,42]. A recent
nationwide surveillance study in 2011, including 12 medical
centres across China, showed a mean MRSA rate of 45.8%
among all clinical S. aureus isolates. The epidemiology in Hong
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TABLE 1. Prevalence of methicillin-resistant Staphylococcus aureus in Asian countries
Region/Years
Source
of isolates
No of study
site(s)/department
% Oxacillin
resistance Reference
East Asia
China
1998–1999 Clinical Multiple (n = 3) 27.8 SENTRY study [7]
Blood Multiple (n = 3) 26.9 SENTRY study [7]
1999–2001 Clinical Multiple (n = 3) 13 SENTRY study [29]
2004–2005 Clinical Multiple (n = 17) 62.9 [41]
2005 Clinical Multiple (n = 16) 50.5 [42]
2011 Clinical Single 68.1 [194]
2011 Clinical Multiple (n = 12) 45.8 [195]
Hong Kong SAR
1984–1986 Nosocomial
Blood
Single 46 [43]
1998–1999 Clinical Single 69.8 SENTRY study [7]
1998–1999 Blood Single 58.2 SENTRY study [7]
1998–1999 Clinical Single 73.8 SENTRY study [28]
1999–2001 Clinical Single 55 SENTRY study [29]
2004–2006 Nosocomial Single 56.8 ANSORP study [44]
2011 Clinical Single 28 [31]
Japan
1985 Clinical Single 5.6 [196]
1988 Clinical Single 50.0 [196]
1990 Clinical Multiple (n = 43) 58.6 [27]
1998–1999 Clinical Multiple (n = 3) 69.5, 71.6 SENTRY study [7,28]
1998–1999 Blood Multiple (n = 3) 66.8 SENTRY study [7]
1999–2001 Clinical Multiple (n = 3) 67 SENTRY study [29]
2011 Clinical Multiple (n = 4) 41 [31]
Korea
1986–1988 Blood Single 21.6 [22]
1989–1996 Blood Single 60.4 [22]
1998 Clinical Multiple (n = 25) 72 [30]
1999–2001 Clinical Multiple (n = 8) 64 [197]
2004–2006 Nosocomial Multiple (n = 7) 77.6 ANSORP study [44]
2011 Clinical Multiple (n = 2) 73 RRS programme [31]
Taiwan
1976–1978 Nosocomial Single 0 [23]
1981–1986 Nosocomial Single 20.2 [15]
Nosocomial Single/ICU 27.8 [15]
1987–1992 Nosocomial Single 31.4 [15]
Nosocomial Single/ICU 58.5 [15]
1993–1998 Nosocomial Single 64.8 [15]
Nosocomial Single/ICU 86.9 [15]
1999 Nosocomial Single 69.3 [15]
Nosocomial Single/ICU 87.4 [15]
1998–1999 Clinical Multiple (n = 3) 59.6, 61.1 SENTRY study [7,28]
Blood Multiple (n = 3) 46.7 SENTRY study [7]
1999–2001 Clinical Multiple (n = 3) 60 SENTRY study [29]
2000 Clinical Multiple (n = 12) 53–83 [198]
2000 Clinical Multiple (n = 21) 60.0 TSAR study [26]
2000 Nosocomial Single 74 [198]
2000 Blood Single 68.8 [33]
2004–2006 Nosocomial Multiple (n = 3) 65.0 ANSORP study [44]
2010 Blood Single 55.9 [33]
Southeast Asia
Indonesia
2011 Clinical Single 28 [31]
Malaysia
1996 Clinical Multiple (n = 3) 39.7 [199]
2011 Clinical Single 32 [31]
Philippines
1999–2001 Clinical Single 8 SENTRY study [29]
2004–2006 Nosocomial Single 38.1 ANSORP study [44]
2011 Clinical Single 59 [31]
Singapore
1989–1991 Clinical Single 39 [200]
1998–1999 Clinical Single 62.3 SENTRY study [7,28]
1998–1999 Blood Single 60.6 SENTRY study [7]
1999–2001 Clinical Multiple (n = 2) 52 SENTRY study [29]
2006 Clinical Multiple (n = 6) 35.3 [45]
2006 Clinical Multiple/ICU (n = 6) 46.7 [45]
2006 Blood Multiple (n = 6) 39.8 [45]
2011 Clinical Single 52 [31]
Thailand
2000–2005 Clinical Multiple (n = ?) 24–27 NARST programme [201]
2004–2006 Nosocomial Single 57.0 ANSORP study [44]
2011 Clinical Multiple (n = 2) 53 [31]
Vietnam
2004–2006 Nosocomial Single 74.1 ANSORP study [44]
South Asia
India
1993–1994 Clinical Single 24 [202]
1999 Clinical Single 80.8 [46]
2000–2002 Clinical Multiple (n = ?) 31.1 [203]
2003a Clinical Single 54.9 [204]
2004–2006 Nosocomial Single 22.6 ANSORP study [44]
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Kong appeared to be distinct from that in China. MRSA
emerged early in the 1980s in Hong Kong, and a survey in the
Prince of Wales Hospital in 1984–1986 showed MRSA rates of
25–30% and 46% among nosocomial isolates and blood isolates
of S. aureus, respectively [43]. The MRSA rate increased to a
high level of 73.8% in 1998–1999 in SENTRY studies, but
appeared to decline thereafter [7,28,29]. The rate was 56.8%
in 2004–2005 in the ANSORP study [44]. The latest survey of
the RRS programme demonstrated an even lower MRSA rate
of 28% in 2011 [31].
Southeast Asia
Most of the epidemiological data on MRSA in Southeast Asia
were obtained from multinational surveillance programmes
(i.e. RSS, ANSORP, and SENTRY), in which only limited
numbers of hospitals and S. aureus strains were obtained
from each participating country [7,29,31,44]. Nevertheless,
the surveillance data suggested that MRSA was not uncom-
mon in this region, and accounted for a substantial propor-
tion of nosocomial infections. For instance, the ANSORP
study showed MRSA rates of 38.1% for the Philippines, 57%
for Thailand and 74.1% for Vietnam in 2004–2006 [44]. The
data from the most recent multinational study of the RSS
programme in 2011 revealed that the proportion of MRSA
among clinical S. aureus isolates ranged from 28% in Indone-
sia to 59% in the Philippines [31]. A multicentre study
sampling six hospitals in Singapore further showed average
MRSA rates of 35.3% among all clinical S. aureus isolates and
46.7% among S. aureus isolates from patients in inten-
sive-care units [45].
South Asia
The proportion of MRSA among S. aureus clinical isolates was
strikingingly high in South Asia, and a rate of 80.8% was
reported in an Indian hospital in 1999. The 2004–2006
ANSOPR study showed a rate of 86.5% among nosocomial
S. aureus isolates in Sri Lanka [44,46]. However, the MRSA
rate appeared to vary signiﬁcantly between distinct hospitals
and different time periods. Two multicentre studies in India
showed MRSA rates of 41% and 45%, respectively, in 2008–
2009 and 2011 [31,47]. Another multicentre study of four
hospitals in Pakistan showed a similar rate, of 41.9%, in 2006–
2008 [48].
Molecular epidemiology of HA-MRSA in Asia
Taiwan. The majority of nosocomial MRSA isolates in the
1990s in Taiwan belonged to strains of sequence type (ST) 254
with SCCmec IV and clonal complex (CC) 239 (mainly ST239
or ST241) with SCCmec III [25]. The ST254-SCCmec IV
strains prevailing in the early 1990s did not possess Panton–
Valentine leukocidin (PVL) genes, and gradually lost their
predominance to CC239 in the late 1990s. In 2000, 73% of 597
clinical MRSA isolates collected from six major hospitals in
Taiwan belonged to CC239 [49]. It was estimated that 95% of
MRSA strains from another institute in northern Taiwan also
belonged to ST239 or ST241 with SCCmec III or SCCmec IIIA
[50]. The CC239 clone predominated among nosocomial
MRSA strains, and had island-wide dissemination in the late
1990s and early 2000s. However, with time, we found a
continuous change in the molecular epidemiology, and another
pandemic clone, ST5-SCCmec II, and the dominant Asian
CA-MRSA clone, ST59, emerged as signiﬁcant causes of
nosocomial BSIs attributable to MRSA [51]. A recent study
characterizing MRSA bloodstream isolates from six major
hospitals collected in 2010 further indicated the waning
dominance of CC239, the increasing rates of ST5 and ST59,
and the emergence of few minor genotypes (CJ Chen,
unpublished data) (Fig. 1).
Korea. ST5 and ST239 have been the two predominant MRSA
clones in Korean hospitals since 1996 [52–55]. The majority of
the ST5 strains carried SCCmec II elements, whereas most of
the ST239 strains carried SCCmec III or SCCmec IIIA [52–54].
The ST5-SCCmec II clone was among the pandemic MRSA
clones, known as New York/Japan clones, that were widely
distributed in North America and Europe [56]. This clone
prevailed in Korean and Japanese hospitals in the 1990s, and
gradually spread to other Asian countries, including Taiwan,
Table 1 (Continued)
Region/Years
Source
of isolates
No of study
site(s)/department
% Oxacillin
resistance Reference
2008–2009 Clinical Multiple (n = 15) 41 [47]
2011 Clinical Multiple (n = 5) 45 [31]
Pakistan
2006–2008 Clinical Multiple (n = 4) 41.9 [48]
Sri Lanka
2004–2006 Nosocomial Single 86.5 ANSORP study [44]
ICU, intensive-care unit; RRS, Regional Resistance Surveillance.
aPublished year; study year not reported.
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Hong Kong SAR, and China, in the 2000s [51,57–59]. The
ST239 MRSA strains had extremely high rates of resistance
(>95%) to trimethoprim–sulphamethoxazole, ciproﬂoxacin,
tobramycin, gentamicin, erythromycin, and tetracycline. The
ST5 strains had lower frequencies of drug resistance, and were
susceptible to trimethoprim–sulphamethoxazole [54,60]. With
the increasing incidence of CA-MRSA strains, the strains of the
dominant community genotype, ST72-SCCmec IV/IVA, also
emerged as a signiﬁcant cause of HA-MRSA infections in
Korean hospitals [55,61].
Japan. A molecular epidemiology study covering 1979–1999
demonstrated that the majority of MRSA strains before 1985
in Japan were ST30, possessed SCCmec IV or SCCmec I,
produced type 4 coagulase, and carried PVL genes at a high
frequency [57]. A substantial proportion of the isolates were
from outpatients, suggesting that the PVL-positive
ST30-SCCmec IV strains might have spread in both the
community and in hospitals in Japan before 1985. The
predominance of ST30 strains waned in the 1990s, and
ST5-SCCmec II became the most dominant MRSA clone,
accounting for >95% of clinical MRSA strains in Japanese
hospitals [57]. Most of the MRSA strains isolated after 1990
were highly resistant to tetracycline, levoﬂoxacin, and imipe-
nem, to which the majority of MRSA strains before 1985 were
susceptible [57].
Hong Kong SAR and China. The MRSA isolates collected in
1988–2000 in the Prince of Wales Hospital in Hong Kong were
clustered into two major phage types and ﬁve pulsotypes. The
strains of two dominant pulsotypes (types A and B) belonged
to the ST239-SCCmec III lineage [62,63]. Another multicentre
study showed that a major clone (ST239-SCCmec III, 50%) and
two minor clones (ST5-SCCmec II, 18%; ST45, 13%) predom-
inated among MRSA bloodstream isolates from four hospitals
in Hong Kong during 2000–2001 [58]. ST239-SCCmec III/IIIA
FIG. 1. Current clonal distributions of dominant healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) and community-asso-
ciated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains in East, Southeast and South Asia. The prevalent clone(s) are indicated as
multilocus sequence types (STs) followed by the SCCmec type. For CA-MRSA strains, the superscript ‘+’ indicates the presence of Panton–Valentine
leukocidin (PVL) genes. The superscript ‘’ indicates the absence of PVL genes.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 605–623
CMI Chen and Huang S. aureus in Asia 609
has also been the most dominant nosocomial MRSA clone in
China since the late 1990s [50,64]. A nationwide study,
including 18 hospitals in 14 cities in 2005–2006, showed that
77.1% of the MRSA clinical isolates belonged to the
ST239-SCCmec III lineage, and that 15.5% belonged to the
ST5-SCCmec II lineage [59]. Most of the ST239 strains were
resistant to tetracycline, erythromycin, clindamycin, gentami-
cin, tobramycin, and ciproﬂoxacin [58,59]. ST5 strains were
also multiresistant to the above antibiotics, except for
clindamycin. Most of the ST45 strains in Hong Kong were
susceptible to multiple non-b-lactams (except for clindamycin)
and carried SCCmec IV, and they were considered to consti-
tute the major CA-MRSA clone in Hong Kong. ST45 strains
were also increasingly identiﬁed among MRSA bloodstream
isolates during 1995–2005 in a multicentre study in Hong Kong
[65].
Southeast Asia. Molecular typing of MRSA strains collected
during 1998–2003 from Indonesia, the Philippines, Singapore,
Thailand and Vietnam indicated that the majority of the strains
belonged to the ST239 or ST241 lineage with SCCmec III/IIIA
[64]. ST239-SCCmec III was also the dominant clone among
MRSA clinical isolates in Singapore during 2006–2010. Similarly
to the situation in East Asia, the molecular epidemiology was
changing, and the ST239 clone among HA-MRSA was also
gradually replaced by the strains of community genotypes,
namely ST22-SCCmec IV and ST45-SCCmec IV [66].
South Asia. ST239-SCCmec III was the dominant genotype
among hospital-onset MRSA isolates in Pakistan in 2006–2007.
The molecular features of HA-MRSA strains were not
comprehensively evaluated in India. A single-institute study,
including 50 MRSA isolates causing skin and soft tissue
infections (SSTIs) in southern India in 2011, showed that
ST239-SCCmec III strains accounted for 32% of all isolates,
and were multiresistant to mupirocin, amikacin, co-trimoxaz-
ole, erythromycin, rifampin and tetracycline with high fre-
quencies.
VISA, heterogeneous VISA (hVISA) and
VRSA in Asia
VISA
S. aureus strains with reduced susceptibility to vancomycin
were ﬁrst identiﬁed in 1996, when a strain (Mu 50) with a
vancomycin MIC of 8 mg/L was isolated from the surgical
wound of an infant in Japan [67]. Given the high incidence of
MRSA and the common use of glycopeptides in this region, the
emergence of vancomycin-non-susceptible strains was not
surprising. Fortunately, it appeared that the VISA strains
(vancomycin MIC of 4–8 mg/L according to CLSI criteria after
2006) had not disseminated widely in Asian countries, but
were identiﬁed only sporadically from patients who had
previously been exposed to glycopeptides or were on
long-term glycopeptide therapy for persistent staphylococcal
infections [68–71]. In 2003, a nationwide study screening 1000
clinical MRSA isolates from ten hospitals in Taiwan showed
only two VISA isolates (0.2%) [72]. A multinational study
screening 1357 clinical MRSA isolates from 12 Asian countries
in 2004 identiﬁed no VISA strain [73]. Molecular typing of the
reported VISA strains indicated that the strains belonged to
distinct clones that had been endemic in hospitals or commu-
nities [68,74,75]. The data supported the limited spread of
VISA internationally. Nevertheless, dissemination of the VISA
strains in a single institute might have occurred, and should not
be overlooked. A report from Taiwan characterizing 43 VISA
strains in a medical centre demonstrated that all of the isolates
shared the same agr and SCCmec types, and had at least 80%
similarity of band patterns in pulsotyping, suggesting clonal
spread of the VISA strains in this hospital [71]. Although
transmission between facilities or countries was seldom
documented, strict control measure should be applied to
affected patients to prevent further dissemination of the VISA
strains.
hVISA
hVISA strains are susceptible to vancomycin when tested with
routine methods (≤2 mg/L) but contain subpopulations with
MICs in the vancomycin-intermediate range (4–8 mg/L). The
hVISA phenotype has been considered to be an essential step
during the conversion of vancomycin-susceptible S. aureus and
VISA phenotypes, and is associated with poor clinical outcome
in patients with invasive staphylococcal infections. A national
surveillance study in Japan in 1996–1997 demonstrated that
9.3% and 1.3% of clinical MRSA isolates, respectively, from
university hospitals and non-university hospitals/clinics showed
heterogeneous resistance to vancomycin (hVISA phenotype)
[76]. However, with the same screening method, another
nationwide study in Japan failed to identify any hVISA strain
after screening 6625 clinical MRSA isolates [77]. The reason
for this discrepancy remains unknown. Following the reports
in Japan, hVISA and VISA strains were identiﬁed in several
Asian countries/regions, including Korea, Thailand, Taiwan,
Singapore, China, India, and Hong Kong [11,52,68,69,74,78–
83]. Because there is no standard method for screening for
hVISA, the reported incidence of hVISA strains may not be
directly comparable between different regions. A multinational
study that screened 1357 MRSA isolates from 12 Asian
countries in 1997–2000, using brain–heart infusion agar plates
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containing 4 mg of vancomycin per litre, showed that hVISA
accounted for 4.3% of the MRSA isolates, ranging from 2.1% in
Thailand to 8.2% in Japan. hVISA strains were also found
among isolates from the Philippines and Vietnam in this study.
VRSA
Isolates with high-level resistance to vancomycin (VRSA
strains; vancomycin MIC of ≥16 mg/L as deﬁned by the CLSI)
have remained very rare in upper-middle income and high--
income countries in Asia. However, the condition is worrying
in resource-limited countries, especially in South Asia, from
which most VRSA strains were reported [10,11]. During 2002
and 2005, four isolates with vancomycin MICs of 16–64 mg/L
were identiﬁed in northern India by screening 783 clinical
S. aureus isolates with the agar dilution method [11]. None of
the VRSA isolates carried vanA or vanB. Another clinical VRSA
isolate (vancomycin MIC of 64 mg/L), identiﬁed in Kolkata in
2005, harboured vanA [10]. The vanA gene integrated into a
plasmid has been shown to originate from vancomycin-resis-
tant Enterococcus faecalis strains, and is associated with
high-level vancomycin resistance in VRSA strains [84–87]. As
most of the reported VISA and VRSA isolates were clinical
isolates, it was noteworthy that two nasal VISA isolates
(vancomycin MIC of 8 mg/L) carrying vanA were identiﬁed
during a routine nasal carriage survey of VISA/VRSA strains in
an intensive-care unit in northern India [9]. Asymptomatic
colonization by vanA-positive S. aureus raised concerns about
the spread of VRSA strains in local hospitals and to
neighbouring countries. Given the high incidence of MRSA,
uncontrolled access to antibiotics, and the emergence of
strains with high-level resistance to vancomycin, an active
surveillance system to closely monitor the real-time condition
of S. aureus in this region is needed.
CA-MRSA in Asia
CA-MRSA has become widespread in many developed
countries during the past decade [88,89]. CA-MRSA infection
is deﬁned as any MRSA infection diagnosed in an outpatient
or within 48 h of hospitalization if the patient lacks the
following HA-MRSA risk factors: haemodialysis, surgery,
residence in a long-term-care facility or hospitalization during
the previous year, the presence of an indwelling catheter or
percutaneous device at the time of culture, or previous
isolation of MRSA from the patient [90]. However, various
MRSA clones have spread between the community and
hospitals, particularly CA-MRSA transmitted in hospital
settings, making the distinction between CA-MRSA and
HA-MRSA difﬁcult [44,91].
In addition to epidemiological features, CA-MRSA strains
differ from HA-MRSA strains in their molecular characteristics
[88,89]. CA-MRSA isolates usually carry SCCmec IV or
SCCmec V, lack multiple antibiotic resistance, except to
b-lactams, and frequently have different exotoxin gene proﬁles,
e.g. PVL genes [88,89,92,93]. The major clinical manifestations
are SSTIs, but severe life-threatening infections such as
necrotizing fasciitis, necrotizing pneumonia and severe sepsis
have been reported [88,89,94,95].
There have been no or few reports describing the epide-
miology, particularly molecular epidemiology, of CA-MRSA in
most Asian developing countries [6,44]. According to the
published reports, the incidence of CA-MRSA in Asia varies
markedly among countries. However, different study designs
make comparisons among countries difﬁcult, or even impos-
sible. In a recent ANSORP study conducted in 17 hospitals in
eight countries, namely Korea (seven hospitals), Taiwan
(three), Hong Kong (one), Thailand (two), the Philippines
(one), Vietnam (one), India (one), and Sri Lanka (one) [44], the
rate of MRSA among community-associated S. aureus infections
ranged from 2.5% to 39%, and the rates were >30% for the
Philippines (28/93), Vietnam (197/654), Taiwan (94/270), and
Sri Lanka (19/49), and <10% for India (2/46), Hong Kong (7/82),
and Thailand (3/122). Except for Korea, Taiwan, and Hong
Kong, this study is the only report of local epidemiological data
regarding CA-MRSA available for the ﬁve developing countries.
The selective reports regarding the epidemiology of
CA-MRSA clinical isolates and the nasal carriage rate of MRSA
among populations from Asian countries are summarized in
Tables 2 and 3, respectively.
East Asia: Taiwan, China, Japan, and Korea
. After it was ﬁrst reported in 2002, the rate of MRSA among
childhood community-associated S. aureus infections increased
signiﬁcantly from 9.8% (17/173) in 1999–2000 to 56% (102/
183) in 2004–2005 in Taiwan [96,97]. CA-MRSA infections
were relatively uncommonly reported in adults in Taiwan. In a
hospital-based retrospective/prospective study conducted
from 2001 to 2006, the rate of methicillin resistance among
community-associated S. aureus BSIs in adults was 14% (30/
215) [98]. The nasal MRSA carriage rate among children
presenting for well-child healthcare visits and/or schoolchil-
dren also increased signiﬁcantly in Taiwan, from 1.9% (5/262)
in 2001 to 7.8% (473/6057) in 2005–2008 [99,100]. In contrast,
only 3.8% of 3098 adults presenting for health examination in
2007 had nasal MRSA colonization [101]. Carriage in healthy
children and adults may accelerate the spread of MRSA in the
community in Taiwan [96].
In China, Zhang et al. [102] analysed 4254 S. aureus strains
collected from the ﬁve largest paediatric hospitals during
ª2014 The Authors
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2005–2006, and found that 73 (1.7%) isolates were MRSA and
38 (0.9%) were CA-MRSA. At Beijing Children’s Hospital, in
1104 children with SSTIs during 2008–2009, 14 (4%) of 351
community-associated S. aureus infections were caused by
MRSA [103]. The rate of nasal MRSA carriage among healthy
persons from a Chinese medical college campus was 3%, but
the nasal MRSA isolates showed considerable molecular
heterogeneity [104]. In a recent countrywide study, 6.6% of
1141 HA-MRSA isolates collected from 69 hospitals during a
6-month period in 2011 had typical CA-MRSA features,
suggesting penetration of CA-MRSA into the hospitals [105].
In Japan, c. 17–20% of S. aureus isolates from bullous
impetigo obtained during the early 2000s were CA-MRSA. In
a recent nationwide survey conducted in 2008–2009, although
94% of 857 clinical isolates were categorized as HA-MRSA, the
proportion of SCCmec IV was 20.0% [106]. In a recent study in
Okinawa, conducted in 2008–2010, in 36% of 274 outpatients
with SSTIs caused by S. aureus, the strains were MRSA, and 12
of 17 PVL-positive strains were MRSA. Nine MRSA isolates
were ST8/SCCmec IV, identical to USA300 [107]. The nasal
MRSA colonization rate ranged from 0.7% for 426 paediatric
outpatients, to 3.7% for 136 healthy children, to 4.3% of 818
children attending day-care centres/kindergartens in Japan
[108]. Speciﬁcally, in Tokyo and Niigata, of the 349 trains
sampled, 2.3% were positive for MRSA. Public transport could
have contributed to the spread of CA-MRSA [109].
In Korea, the emergence of CA-MRSA infections was
initially reported in Kyungnam Province in 2004–2005, and
ST72 accounted for 11 of 23 CA-MRSA isolates [110]. In 2005,
a hospital laboratory-based survey was conducted in seven
major hospitals. CA-MRSA accounted for 5.9% of 1900 MRSA
isolates [111]. The nasal MRSA carriage rate in children
increased from 6.1% (18/296 outpatients) in 2005–2006 to
9.3% (40/428 healthy children attending day-care centres) in
2008 [112,113]. In addition, several studies showed that the
community strain ST72-SCCmec IV/PVL-negative accounted
for a substantial proportion of healthcare-associated infections
in the hospitals [61,114,115], suggesting that CA-MRSA strains
are emerging as major causes of healthcare-associated infec-
tions in Korea [116,117].
Southeast Asia
Since it was ﬁrst reported in 2004, the incidence of CA-MRSA
has been rapidly increasing in the Hong Kong community
[118]. During a 4-month period from November 2006 to
February 2007, in 42% of 298 patients with purulent SSTIs at
the emergency departments in six regional hospitals, the
infections were caused by S. aureus, and 10.4% of the 126
S. aureus isolates were PVL-positive CA-MRSA [119].
CA-MRSA infection or carriage was found in six (13%) of 46T
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household contacts [120]. In a study conducted in 2009–2010,
Ho et al. [121] found that the nasal/nasopharyngeal MRSA
carriage rate was 1.3% for 2211 children aged 2–5 years
attending 79 day-care centres and 113 kindergartens in Hong
Kong.
In Singapore, sporadic CA-MRSA isolates were found from
the microbiology archives of the Singapore General Hospital
from January 2001 to April 2004, yielding eight possible
CA-MRSA cases, which were completely unrelated to each
other genetically and epidemiologically [122]. Since then,
however, non-systematic data collection has revealed that
the number of infections has increased progressively [123],
with the emergence of a predominant ST30-IVc clone,
suggesting local transmission.
S. aureus reservoirs were deﬁned in the community and
hospitals from 329 nasal carriage isolates obtained from 3995
healthy individuals in Java, Indonesia. Only one isolate (0.3%)
was identiﬁed as MRSA [124].
In Malaysia, a retrospective study conducted in 2002–2005
and a prospective study conducted in 2006–2007 identiﬁed
multidrug-susceptible MRSA in 13 patients: two (0.5%) in 2003,
two (0.6%) in 2006, and nine (3.1%) in 2007. These isolates
carried SCCmec IV, and predominantly caused SSTIs. There
was considerable clonal diversity [125]. During 2006–2008, 20
(3.2%) of 628 MRSA isolates collected from nine hospitals in
Malaysia carried SCCmec IV. Eleven STs were found. Nine of
20 isolates were CA-MRSA, and eight were ST30/PVL-positive,
and not multiresistant [126]. Among 110 MRSA isolates
collected from a tertiary-care hospital in 2008, 13.6% carried
SCCmec IV, and most belonged to ST22, a clone endemic in
India [127]. In a nasal carriage survey, one of 346 healthy adults
carried an MRSA strain, which was different from the hospital
strain [128].
In Thailand, at Siriraj Hospital in 2005, 186 (41.5%) of 669
S. aureus isolates from 448 patients were MRSA. Three
isolates (0.9% of total MRSA) from two patients (1.1% of
MRSA-infected patients) were CA-MRSA. The prevalence of
CA-MRSA infections in hospitalized patients was low [129].
The rate of MRSA nasal carriage was 1% (two of 200) among
healthy young Thai adults. Both carriers had healthcare risk
factors, and both MRSA isolates carried SCCmec II but were
multidrug-susceptible [130]. However, none of 128 medical
students had nasal MRSA carriage in a later study [131].
In Cambodia, CA-MRSA from three different north-wes-
term Cambodian provinces was identiﬁed in 2006–2007 at
Angkor Hospital for children [132]. Paediatric MRSA carriage
was found in 87 (3.5%) of 2485 children from the outpatient
department and in six (4%) of 145 inpatients. Five genotypes
were identiﬁed, with ST834 being the most common (91%)
[133].
In Vietnam, an outbreak of MRSA infection associated with
vaccination was reported in 2007. A genetically indistinguish-
able MRSA strain was isolated from injection site abscesses
from four children, and from nasal and throat swabs from their
vaccinator. All isolates carried PVL genes and SCCmec V, and
belonged to ST59, the endemic CA-MRSA clone in Taiwan
[134].
South Asia
In India, during 2000–2001, MRSA was responsible for 22
(10.9%) of 202 cases of community-associated pyoderma
caused by S. aureus [135]. Between 2006 and 2009, 412 MRSA
isolates from Mumbai were evaluated, and it was found that
34% of the isolates carried SCCmec IV and 41% carried
SCCmec V. Of the patients with SCCmec IV and SCCmec V
isolates, 72% had no risk factors for MRSA acquisition,
demonstrating the emergence of CA-MRSA in Mumbai.
ST22-SCCmec IV and ST772-SCCmec V were identiﬁed
[136]. However, the proportion of MRSA among commu-
nity-onset S. aureus SSTIs varied markedly between different
cities, from 0% (0/452) in Mumbai [137] to 65% (77/119) in
Andhra Pradesh [138]. The nasal MRSA carriage rate was
1.02% among healthy children aged 1 month to 5 years visiting
the outpatient clinics of two hospitals in Ujjain, India [139], the
rate for schoolchildren ranged from 0.31% (4/1300) to 3.9%
(19/489) during the 2000s [140–142], and the rate reached
10% for 1002 preschool children aged 1–6 years in 100
anganwaries (preschools) in 2008–2010, indicating that MRSA
is prevalent in the paediatric population in the community in
India [143].
Major CA-MRSA clones in Asia
The distribution of dominant CA-MRSA clones in Asian
countries and areas is shown in Fig. 1. PVL-positive
ST30-SCCmec IV strains, known as the Southwest Paciﬁc
clone [144], appear to be highly adaptable and transmissible.
ST30 MRSA was the most prevalent type in Singapore,
involving individuals of different ethnic groups [123]; it was
also prevalent in Hong Kong [119] and in The Philippines [44],
and was recently reported in Korea [145]. In Japan,
PVL-positive ST30 MRSA persisted for >30 years (since the
1980s), but it was not the same clone throughout, and after
2002 the prevalent spa19 clone was CA-MRSA [146]. ST30
MRSA has also been found in the USA and Europe, and can
now be considered to be worldwide clone [147,148] (Fig. 1).
In addition to Taiwan, ST59 MRSA was shown to be
prevalent in Hong Kong, and China, and was also identiﬁed in
Vietnam, Japan, and Australia [103,118,134,149,150]. In the
USA, ST59/SCCmec IV CA-MRSA was prevalent in selected
populations, including human immunodeﬁciency virus carriers,
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 605–623
CMI Chen and Huang S. aureus in Asia 615
intravenous drug users and homeless persons in San Francisco
[151]. However, ST59 prevailing in these countries is not a
single clone, but a CC, including a single-locus variant (ST338).
For the strains of ST59, at least two different SCCmec types
(IV and V), two different pulsed-ﬁeld gel electrophoresis
(PFGE) patterns, the presence or absence of PVL genes and
different antibiograms have been found. The Taiwan CA-MRSA
clone, ST59/SCCmec VT/PVL-positive, was distinguished from
the Asia-Paciﬁc clone, ST59/SCCmec IV/PVL-negative, by
enhanced virulence in both humans and an animal infection
model. The evolutionary acquisition of PVL, the higher
expression of a-toxin and, possibly, the loss of a large portion
of the b-haemolysin-converting prophage probably contribute
to its higher pathogenic potential [152].
The major CA-MRSA clone in South Korea,
ST72-SCCmec IVa/PVL-negative, is different from those that
have spread in Asia or internationally. These isolates were also
less multidrug-resistant [110]. The entire genome sequence of
ST72 CA-MRSA was reported recently, and analysed with a
focus on virulence factors; this showed that this strain does
not have considerable differences in virulence factor content
from other CA-MRSA strains (USA300 and USA400) [75].
ST22 and ST772 were the epidemic clones associated with
both community-associated and healthcare-associated infec-
tions in India, and seemed to progressively replace the ST239
clone in hospitals [136]. ST772 MRSA was also reported in
Bangladesh [153] and Malaysia [154], and was recently
exported to Ireland [155]. ST22-SCCmec IV MRSA strains
(CC22) corresponded with the epidemic UK EMRSA-15 strain
[155,156], and were also reported in Japan [157] and Malaysia
[127]. The success of ST22 CA-MRSA as both a colonizer and
a pathogen could result from the combination of its strong
bioﬁlm formation and other virulence factors [157].
All of these Asian CA-MRSA clones were recently identiﬁed
in several European countries, such as Denmark, Ireland, the
UK, and Norway [158], through travel or immigration of Asian
workers. In contrast, USA300 CA-MRSA-infected cases have
been reported from Japan [159,160], South Korea [161,162],
Taiwan (unpublished), and Singapore [163], and have even
resulted in outbreaks, implying that this clone has penetrated
into Asian countries. Further surveillance studies should be
conducted to determine whether this clone has spread to
other Asian countries.
The true incidence of CA-MRSA is difﬁcult to ascertain, and
has probably been underestimated, because most data were
obtained from hospital-based surveys, not population-based
studies. In the resource-restricted countries in Asia, many
patients are treated as outpatients without any cultures being
performed for S. aureus or identiﬁcation of organisms to the
strain level. Nasal colonization surveys may underestimate the
true incidence of S. aureus disease, because MRSA colonization
of other body sites is common [164].
Factors that are linked to CA-MRSA infections, such as high
antimicrobial consumption, overcrowding, lack of water,
resulting in poor hygiene, insect bites and scabies are prevalent
throughout the developing world. Interventions for the
control and prevention of CA-MRSA infections include general
hygiene and cleaning measures to prevent transmission,
antibiotic stewardship programmes, screening and decoloni-
zation in selected conditions, and, in the future, vaccination
[165,166]. Educating patients and clinicians is mandatory to
control CA-MRSA.
LA-MRSA in Asia
In addition to being a human pathogen, S. aureus causes an
array of infections in economically important livestock animals,
particularly pigs [167–169]. A speciﬁc MRSA ST (ST398) has
been found to be associated with various animals and humans
across European countries and North America [170–174].
ST398 has the capacity to colonize multiple host species,
including pigs, cows, sheep, and poultry, may facilitate coloni-
zation in animal workers and in people with animal contact,
and can cause severe infections in humans. Several cases of
ST398 infection in humans have been reported in European
countries, Hong Kong, and China [58,172,175–178].
The incidence of MRSA among pigs in Asian countries was
lower than that for western countries. The rates reported
from Asian countries were 16–21.3% for Hong Kong
[179,180], 4–42.5% for Taiwan [181–183], 11.4% (58/509)
for China [184], 3.2% (21/657) for Korea [185], 1.4% for
Malaysia [186], and 0.9% for Japan [187]. Fang et al. [183]
indicated that the nasal MRSA carriage rate among pigs was
affected by the sampling location (pig farms or auction
markets), the size of pig farms, and the age of the pigs sampled.
Rather than ST398, CC9 (ST9 and single-locus variants) is
the most prevalent LA-MRSA clone in most Asian countries,
such as China, Hong Kong, Taiwan, Thailand, and Malaysia, but
not in Japan and Korea. In Japan, the main strain was found to
be ST221 [187], whereas ST398/t034 and ST541/t034 were
predominant in Korea [185]. Although the LA-MRSA isolates
in most Asian countries shared a common ST, namely ST9, the
molecular characterizations of these LA-MRSA isolates were
not the same: they had different SCCmec types and spa types
[12,179–184,186,188].
The nasal MRSA colonization rate among pig farmers and
related personnel in Asian countries was lower than that in
European countries (20–45%), and the rates reported from
Asian countries were 5.5% (5/90) for Malaysia [154], 1.7% (2/
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120) for China [184], and 13% (13/100) for Taiwan [183].
According to the report from Taiwan [183], ten of 13 MRSA
isolates from humans belonged to ST9, and the PFGE pattern
of these human MRSA isolates was indistinguishable from that
of MRSA isolates from pigs. These ﬁndings suggest that ST9
probably spread via human contact rather than animal contact,
a scenario demonstrated for ST398 MRSA transmission in
Europe [189,190].
Human infections with ST398 LA-MRSA have been
reported in Europe since it was ﬁrst identiﬁed in pigs
[169,176,177,191–193], but, despite the prevalence of ST9
MRSA among pigs in Asia, infections caused by this clone in
animals and humans were not addressed in the literature.
However, Wan et al. [12] found that, among the isolates
collected from the Taiwan Surveillance of Antimicrobial
Resistance, a biennial national surveillance programme, ﬁve
human clinical isolates of ST9-t899/PVL-negative were iden-
tiﬁed and were isolated in 1998, 2004, 2006 (two isolates),
and 2010; three were from outpatients and two were from
inpatients. A highly homogeneous virulence genotype and
homogeneous genomic proﬁles were identiﬁed among the
ST9 MRSA isolates of human and pig origin. However, the
PFGE patterns were different (personal communication,
Tsai-Ling Lauderdale, National Health Research Institute,
Taiwan). To better understand the epidemiology and
transmission of LA-MRSA in Asia, further studies are needed.
Conclusions
S. aureus with resistance to multiple antibiotics continues to be
an important medical organism and to be associated with a
huge disease burden in Asia. The incidence of MRSA in
healthcare facilities in Asia reached its peak in the late 1990s,
and stayed at a plateau level during the 2000s. The emergence
of CA-MRSA after 2000 also occurred in the majority of Asian
countries, with strikingly high incidence rates of >50% in some
regions. The high rates of MRSA in hospitals and communities
have inevitably led to the increased use of glycopeptides and
other anti-MRSA agents, and have promoted the development
of glycopeptide-non-susceptible strains. Given the high trans-
missibility of S. aureus strains and the crowded living condi-
tions in Asia, the VISA and VRSA strains, although only
sporadically reported at present, constitute a substantial public
health threat, especially in resource-poor countries, where
diagnostic facilities are largely lacking and appropriate therapy
is frequently unaffordable. Implementation of surveillance
systems at the international level is urgently needed to gain
insights into the current epidemiology of S. aureus in
the resource-limited Asian countries. In middle-income to
high-income countries with a high incidence of MRSA, effective
infection control strategies, diagnostic culture and the judi-
cious use of antimicrobial agents remain the best methods to
prevent the transmission of MRSA and ease the associated
disease burden.
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